Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biopharmaceutical company developing next-generation immunotherapies, today announced that it will host a virtual event on Monday, November 9, 2026, at 8:30 a.m. ET.David Campbell, Ph.D., President and Chief Executive Officer, will present initial clinical data from the Phase 1 single-ascending-dose study of JANX011 in healthy volunteers. The presentation will review safety, pharmacokinetics and pharmacodynamic